SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization (R44)
The summary for the SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization (R44) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization (R44): This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for projects that were previously funded by NIH SBIR Phase II awards. Projects proposed in response to this FOA must be applicable to one of the following areas: (1) cancer therapeutics; (2) cancer imaging technologies, interventional devices and in vivo diagnostics; or (3) in vitro and ex vivo cancer diagnostics and prognostics. The purpose of this FOA is to facilitate the transition of SBIR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between NIHs SBIR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and technologies. Consistent with the goals of this funding initiative and as required by the SF424 instructions for all Phase II SBIR applications, applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Bridge Award project period. It is expected that the level of this independent third-party funding will equal or exceed the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required..
|Federal Grant Title:||SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization (R44)|
|Federal Agency Name:||National Institutes of Health|
|Grant Categories:||Education Health|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-CA-11-002|
|Type of Funding:||Grant|
|CFDA Descriptions:||Cancer Detection and Diagnosis Research|
|Current Application Deadline:||Apr 07, 2011|
|Original Application Deadline:||Apr 07, 2011|
|Posted Date:||February 3rd, 2011|
|Creation Date:||Feb 03, 2011|
|Archive Date:||May 08, 2011|
|Total Program Funding:||$10,000,000|
|Maximum Federal Grant Award:||$1,000,000|
|Minimum Federal Grant Award:|
|Expected Number of Awards:|
|Cost Sharing or Matching:||No|
- Applicants Eligible for this Grant
- Small businesses
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
- Similar Government Grants
- • Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Rese...
- • Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologi...
- • Innovative Technologies for Cancer-Relevant Biospecimen Science (R21)
- • Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic...
- • Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported R...
- • Image-Guided Cancer Interventions (STTR [R41/R42])
- • An SBIR Initiative for Image-Guided Cancer Interventions (R43/R44)
- • In Vivo Cancer Imaging Exploratory/Developmental Grants
- More Grants from the National Institutes of Health
- • BRAIN Initiative: Exploratory Targeted BRAIN Circuits Projects - eTargetedBCP (R21)
- • BRAIN Initiative: Targeted BRAIN Circuits Projects - TargetedBCP (R01)
- • Tools for Clinical Care and Management of Alzheimers Disease (AD) and its Comorbidities (R...
- • Tools for Clinical Care and Management of Alzheimers Disease (AD) and Its Comorbidities (R...
- • Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (...